| Oxidative phosphorylation |
2.31 |
0.00e+0 |
93/133 (69.92%) |
PPA2;NDUFB5;COX7B;...
|
| DNA replication |
2.18 |
0.00e+0 |
34/36 (94.44%) |
POLE2;PRIM1;RPA3;...
|
| Propanoate metabolism |
2.07 |
0.00e+0 |
30/34 (88.24%) |
LDHB;SUCLG2;DLD;...
|
| Non-alcoholic fatty liver disease |
2.00 |
0.00e+0 |
126/155 (81.29%) |
NDUFB5;CXCL8;COX7B;...
|
| Nucleotide excision repair |
1.95 |
1.67e-3 |
40/47 (85.11%) |
POLE2;RPA3;RFC3;...
|
| Diabetic cardiomyopathy |
1.95 |
1.40e-3 |
162/203 (79.8%) |
CYBA;CYBB;NDUFB5;...
|
| Valine, leucine and isoleucine degradation |
1.93 |
3.59e-3 |
42/48 (87.5%) |
ALDH9A1;AUH;DLD;...
|
| Ribosome |
1.90 |
5.23e-3 |
113/158 (71.52%) |
RPL26L1;MRPL33;MRPL22;...
|
| Thermogenesis |
1.88 |
5.58e-3 |
173/232 (74.57%) |
SMARCD3;NDUFB5;COA1;...
|
| Base excision repair |
1.82 |
1.51e-2 |
29/33 (87.88%) |
POLE2;PARP2;FEN1;...
|
| Staphylococcus aureus infection |
1.82 |
1.37e-2 |
72/95 (75.79%) |
C3;HLA-DMB;CFI;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.80 |
1.33e-2 |
84/100 (84%) |
TNFSF10;CXCL5;CCR1;...
|
| Pertussis |
1.79 |
1.42e-2 |
64/76 (84.21%) |
CXCL5;CASP1;CD14;...
|
| Parkinson disease |
1.77 |
1.56e-2 |
176/249 (70.68%) |
NDUFB5;COX7B;NDUFB3;...
|
| Tryptophan metabolism |
1.75 |
1.67e-2 |
35/42 (83.33%) |
KYNU;ALDH9A1;MAOB;...
|
| Prion disease |
1.74 |
1.73e-2 |
209/273 (76.56%) |
CYBA;CYBB;NDUFB5;...
|
| Terpenoid backbone biosynthesis |
1.73 |
1.92e-2 |
18/22 (81.82%) |
PDSS1;ACAT2;IDI1;...
|
| Complement and coagulation cascades |
1.73 |
1.81e-2 |
76/85 (89.41%) |
TFPI;SERPINA1;F13A1;...
|
| Mismatch repair |
1.72 |
1.76e-2 |
22/23 (95.65%) |
RPA3;RFC3;SSBP1;...
|
| Peroxisome |
1.71 |
1.72e-2 |
72/82 (87.8%) |
PHYH;ECI2;SOD2;...
|
| Systemic lupus erythematosus |
1.71 |
1.71e-2 |
45/135 (33.33%) |
C3;HLA-DMB;FCGR2A;...
|
| Drug metabolism |
1.66 |
2.47e-2 |
78/151 (51.66%) |
ADH5;MGST2;FMO1;...
|
| N-Glycan biosynthesis |
1.66 |
2.44e-2 |
38/50 (76%) |
ALG5;DPM3;ALG8;...
|
| Steroid biosynthesis |
1.65 |
2.41e-2 |
19/20 (95%) |
DHCR7;LIPA;HSD17B7;...
|
| beta-Alanine metabolism |
1.64 |
2.55e-2 |
25/30 (83.33%) |
ALDH9A1;DPYD;ALDH3A1;...
|
| Amyotrophic lateral sclerosis |
1.60 |
3.80e-2 |
267/364 (73.35%) |
CASP1;NDUFB5;COX7B;...
|
| Citrate cycle (TCA cycle) |
1.58 |
4.75e-2 |
30/30 (100%) |
SDHD;IDH1;SUCLG2;...
|
| Huntington disease |
1.57 |
4.94e-2 |
233/306 (76.14%) |
NDUFB5;COX7B;GPX1;...
|
| Insulin secretion |
-1.72 |
1.14e-2 |
75/86 (87.21%) |
KCNN1;PLCB4;RAB3A;...
|
| Colorectal cancer |
-1.73 |
1.14e-2 |
84/86 (97.67%) |
TGFBR1;BAX;EREG;...
|
| PI3K-Akt signaling pathway |
-1.73 |
1.18e-2 |
317/354 (89.55%) |
EREG;BDNF;TCL1B;...
|
| Human papillomavirus infection |
-1.75 |
9.94e-3 |
284/331 (85.8%) |
RBPJL;ATP6V1D;TNXB;...
|
| Bacterial invasion of epithelial cells |
-1.75 |
1.03e-2 |
59/77 (76.62%) |
PIK3CA;ILK;ARPC5L;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
-1.76 |
1.07e-2 |
70/77 (90.91%) |
ACTN3;CACNG2;ITGA2;...
|
| Synaptic vesicle cycle |
-1.76 |
1.12e-2 |
63/78 (80.77%) |
SLC6A11;ATP6V1G1;AP2M1;...
|
| Melanogenesis |
-1.80 |
7.95e-3 |
74/101 (73.27%) |
CREBBP;FZD7;TYRP1;...
|
| Axon guidance |
-1.80 |
7.21e-3 |
151/182 (82.97%) |
RAC1;PIK3CD;MAPK3;...
|
| Endocytosis |
-1.82 |
3.48e-3 |
198/252 (78.57%) |
NEDD4L;CHMP1A;ARF5;...
|
| ErbB signaling pathway |
-1.82 |
3.66e-3 |
79/85 (92.94%) |
CAMK2A;EREG;ERBB4;...
|
| Breast cancer |
-1.83 |
3.21e-3 |
119/147 (80.95%) |
SP1;RPS6KB1;FGF4;...
|
| Glioma |
-1.84 |
3.39e-3 |
67/75 (89.33%) |
E2F2;CAMK2A;BAX;...
|
| GnRH signaling pathway |
-1.84 |
3.59e-3 |
80/93 (86.02%) |
PLCB4;MMP2;CAMK2A;...
|
| Estrogen signaling pathway |
-1.86 |
3.81e-3 |
119/137 (86.86%) |
GNAO1;PLCB4;SP1;...
|
| Bladder cancer |
-1.87 |
2.44e-3 |
40/41 (97.56%) |
MAP2K1;HRAS;DAPK3;...
|
| Endometrial cancer |
-1.88 |
1.74e-3 |
56/58 (96.55%) |
PIK3CD;MAPK3;RAF1;...
|
| MAPK signaling pathway |
-1.90 |
1.88e-3 |
272/294 (92.52%) |
RAP1A;EFNA1;HSPB1;...
|
| MicroRNAs in cancer |
-1.90 |
2.03e-3 |
146/310 (47.1%) |
SERPINB5;MAP2K2;APC2;...
|
| TGF-beta signaling pathway |
-1.93 |
1.11e-3 |
81/94 (86.17%) |
SP1;RPS6KB1;HAMP;...
|
| Chronic myeloid leukemia |
-1.93 |
1.22e-3 |
72/76 (94.74%) |
E2F2;TGFBR1;BAX;...
|
| ECM-receptor interaction |
-1.94 |
1.35e-3 |
80/88 (90.91%) |
LAMA3;COL9A1;CD36;...
|
| Gastric cancer |
-1.95 |
1.52e-3 |
122/149 (81.88%) |
RPS6KB1;FGF4;E2F2;...
|
| Thyroid cancer |
-1.96 |
1.74e-3 |
36/37 (97.3%) |
CCND1;KRAS;MAP2K2;...
|
| Signaling pathways regulating pluripotency of stem cell... |
-1.96 |
2.03e-3 |
110/143 (76.92%) |
HOXB1;PAX6;PIK3CD;...
|
| Adherens junction |
-1.97 |
2.44e-3 |
63/71 (88.73%) |
SORBS1;FARP2;SNAI1;...
|
| Renal cell carcinoma |
-1.98 |
3.05e-3 |
68/69 (98.55%) |
RAC1;PIK3CD;MAPK3;...
|
| Proteoglycans in cancer |
-1.99 |
4.06e-3 |
172/205 (83.9%) |
RPS6KB1;MMP2;FZD9;...
|
| Regulation of actin cytoskeleton |
-2.05 |
6.10e-3 |
185/218 (84.86%) |
CHRM4;RAC1;PIK3CD;...
|
| Focal adhesion |
-2.07 |
1.22e-2 |
180/201 (89.55%) |
RAC1;PIK3CD;MAPK3;...
|
